leisure time -WSS

leisure time

author：leisure time 2025-09-30 16:29:44 - browse：7384

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

A pill being developed by Danish drugmaker Novo Nordisk may lead to greater weight loss than the obesity therapy Wegovy, the company reported Thursday, citing early data.

In a Phase 1 trial, participants experienced an average of 13.1% weight loss after 12 weeks of taking the experimental oral medicine amycretin, according to data presented at an investor meeting. In comparison, in an earlier Phase 3 trial of the injectable drug Wegovy, people taking Wegovy lost about 6% of their body weight over the same time period.

Novo Nordisk has been on a mission to capitalize on its success with Wegovy, which brought in $4.5 billion in sales last year. (The drug is also sold as a diabetes treatment under the name Ozempic. That version of the drug brought in another $14 billion in sales).

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： FDA authorizes Novavax’s updated Covid

WSS

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

Why Charlie Gard's case is so disturbing to Americans

Diversity in clinical trials starts with building trust, experts say

Was Amgen transparent enough on FDA's concern on cancer drug?

UnitedHealth financials solid despite Change Healthcare cyberattack

More tobacco lobbyists active in statehouses

hotspot

leisure time

hotspot

Malaria cases in Florida and Texas: Here’s what you need to know

When women are denied an abortion, their children fare worse than peers

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Why age limits for politicians are a terrible idea

New air purifier tech could be key to improving indoor air quality

MultiPlan and major insurers sued for alleged medical price

Virginia high school admissions case could be legal follow

Senate panel eyes new effort on drug shortages

ChatGPT in medicine: STAT answers readers' burning questions

FTC falls short on scrutinizing hospital mergers, study says

hotspot

Exact Sciences stock tumbles despite strong cancer detection sales

Why rehabilitation engineers need to center patients in their research

What to expect at HLTH 2023, the health care industry conference

UnitedHealth financials solid despite Change Healthcare cyberattack

Analysis of telehealth claims data suggest service duplication

Close Medicare's dangerous gaps in addiction treatment coverage

hotspot

hotspot

entertainment

leisure time